ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2579

Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis

Atul A. Deodhar1, Bojena Bitman2, Yue Yang2 and David Collier3, 1Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, 2Amgen Inc., South San Francisco, CA, 3Amgen Inc., Thousand Oaks, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, etanercept and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease. This analysis evaluated changes in metabolic and lipid CV risk factors in patients with RA treated with etanercept (ETN).

Methods: This was an exploratory analysis in a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ETN in patients with moderate RA despite disease-modifying antirheumatic drug therapy. Adults with active, moderate RA (3.2 <DAS28-CRP ≤5.1) for ≥6 months and receiving a stable dose of methotrexate for ≥8 weeks were randomized 1:1 to receive ETN 50 mg or placebo (PBO) weekly for 12 weeks; after week 12, all patients received ETN 50 mg weekly for 12 weeks. Laboratory tests evaluated baseline, week-12, and week-24 levels of metabolic and lipid analytes, and shifts in grade (low, normal, or high).

Results: In total, 210 patients enrolled: 104 PBO and 106 ETN; 77% female, 86% white, and mean (SD) age 56 (12) years.  There were 14% with a medical history of type 2 diabetes and 30% a medical history of hyperlipidemia or hypercholesterolemia; 22% were receiving statins, 10% oral antidiabetic medications, 3% insulin, and 52% prednisone. Baseline, week-12, and week-24 values for each analyte are listed below. Over 24 weeks, there were no significant changes in metabolic or lipid analytes. Patients with diabetes and hyperlipidemia resembled the overall study population, except for decreases in fasting glucose and insulin through week 12 and slight decreases in hemoglobin A1C through week 24 in diabetics receiving ETN (n=17). For the majority of patients, all analytes were in the normal range at baseline and remained normal at week 24.There were no gross abnormalities in liver function tests. Safety results are consistent with the current safety profile.

Conclusion: Treatment with ETN did not adversely affect the levels of traditional metabolic and lipid CV risk factors in patients with RA. Results in patients with diabetes are hypothesis generating and might be clinically relevant if demonstrated in a larger study.

Analyte, mean (SD)

Baseline

Week 12

Week 24

PBO-ETN

N=104

ETN-ETN

N=106

PBO-ETN

N=104

ETN-ETN

N=106

PBO-ETN

N=104

ETN-ETN

N=106

Fasting glucose, mg/dl

99.0 (30.7)

98.6 (30.3)

95.9 (22.3)

97.3 (26.6)

101.0 (22.8)

100.1 (24.0)

Fasting insulin, mIU/L

14.3 (17.6)

16.0 (34.9)

15.3 (22.4)

13.2 (13.5)

15.0 (18.4)

12.0 (12.1)

Hemoglobin A1C, %

5.7 (0.9)

5.7 (0.7)

5.7 (0.9)

5.6 (0.6)

5.6 (0.9)

5.6 (0.6)

Total cholesterol, mg/dl

195.2 (44.2)

186.6 (37.1)

190.9 (40.7)

184.8 (37.4)

197.0 (41.7)

191.1 (39.6)

HDL, mg/dl

62.0 (18.1)

62.1 (21.7)

60.5 (17.1)

61.6 (18.3)

62.1 (18.5)

62.2 (22.9)

LDL, mg/dl

105.6 (36.3)

97.8 (30.0)

103.2 (35.4)

96.9 (33.2)

105.5 (35.4)

101.7 (31.0)

Triglycerides, mg/dl

135.2 (91.6)

133.1 (80.1)

139.2 (85.5)

131.8 (69.4)

149.6 (104.0)

136.6 (76.2)

Apolipoprotein A1, mg/dL

159.6 (27.8)

160.5 (35.4)

159.2 (28.1)

162.0 (32.8)

163.7 (32.1)

161.6 (38.0)

Apolipoprotein B, mg/dL

91.6 (25.5)

86.2 (22.2)

89.5 (24.7)

84.9 (23.8)

91.8 (24.2)

88.7 (25.0)

Adiponectin, mg/L

11.6 (6.8)

11.5 (8.7)

11.7 (7.4)

11.6 (8.8)

12.3 (7.2)

11.6 (9.1)

Leptin, μg/L

29.3 (20.9)

33.5 (28.5)

30.1 (22.7)

35.6 (30.9)

30.8 (22.7)

34.5 (28.9)

Plasma NT-ProBNP, ng/L

242.0 (554.1)

170.1 (334.6)

232.2 (630.8)

168.2 (297.8)

244.2 (687.5)

164.2 (315.7)

 


Disclosure: A. A. Deodhar, AbbVie, 2,AbbVie, 9,Amgen, 2,Amgen, 9,Boehringer Ingelheim, 2,Boehringer Ingelheim, 9,Janssen Pharmaceutica Product, L.P., 2,Janssen Pharmaceutica Product, L.P., 9,Novartis Pharmaceutical Corporation, 2,Novartis Pharmaceutical Corporation, 9,Pfizer Inc, 2,Pfizer Inc, 9,UCB, 2,UCB, 9; B. Bitman, Amgen, 3,Amgen, 1; Y. Yang, Amgen, 5; D. Collier, Amgen, 3,Amgen, 1.

To cite this abstract in AMA style:

Deodhar AA, Bitman B, Yang Y, Collier D. Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/etanercept-treatment-does-not-adversely-affect-traditional-cardiovascular-risk-factors-in-patients-with-rheumatoid-arthritis/. Accessed May 25, 2022.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/etanercept-treatment-does-not-adversely-affect-traditional-cardiovascular-risk-factors-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.